Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsors and Collaborators: |
National Heart, Lung, and Blood Institute (NHLBI) Transfusion Medicine/Hemostasis Clinical Research Network |
---|---|
Information provided by: | National Heart, Lung, and Blood Institute (NHLBI) |
ClinicalTrials.gov Identifier: | NCT00233246 |
This study will compare patients with mild to moderate prolongation of the INR test who receive FFP infusions prior to invasive hepatobiliary procedures for bleeding complications to patients who do not receive FFP infusions. Bleeding complications will be defined as meeting one or more of the following:
The secondary endpoints of this study will be: 1) The need to perform subsequent procedures (angiography, embolization, additional imaging study including computerized tomography (CT) scan, surgery) to diagnose or to arrest procedure-related bleeding OR the need for subsequent medical therapies (FFP, coagulation factor concentrates, anti-fibrinolytics) to treat procedure-related bleeding between time of procedure and the end of patient's time in the study. If necessary, the relationship of procedure or therapy to procedure-related bleeding will be assessed by an adjudication panel; 2) The predictive value of INR; 3) The effect of study treatment on change in INR; 4) The cost of preventing one bleed; 5) The predictors of bleeding other than INR; 6) The number of transfusion-associated adverse events encountered to prevent one bleed; and 7) The effect of treatment on bleeding grade.
Condition | Intervention | Phase |
---|---|---|
Blood Coagulation Disorders |
Procedure: FFP Infusion |
Phase III |
Study Type: | Interventional |
Study Design: | Prevention, Randomized, Open Label, Placebo Control |
Official Title: | Study of Hemostasis and Invasive Procedures (SHIP: A TMH CTN Study) |
Estimated Enrollment: | 1300 |
Study Start Date: | March 2006 |
Ages Eligible for Study: | 4 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
prophylactic heparin injections into central venous catheters for catheter maintenance, prophylactic heparin (standard or low-dose) for prevention of deep venous thrombosis, and/or aspirin)
United States, Georgia | |
Emory University | |
Atlanta, Georgia, United States, 30322 | |
United States, Iowa | |
University of Iowa Hospitals and Clinics | |
Iowa City, Iowa, United States, 52242 | |
United States, Maryland | |
Johns Hopkins Hospital | |
Baltimore, Maryland, United States, 21287 | |
University of Maryland Medical Center | |
Baltimore, Maryland, United States, 21201 | |
United States, Massachusetts | |
Massachusetts General Hospital | |
Boston, Massachusetts, United States, 02114 | |
United States, Minnesota | |
University of Minnesota | |
Minneapolis, Minnesota, United States, 55455 | |
Mayo Clinic | |
Rochester, Minnesota, United States, 55905 | |
United States, New York | |
Weill Medical College of Cornell University | |
New York, New York, United States, 10021 | |
United States, North Carolina | |
University of North Carolina Hospital | |
Chapel Hill, North Carolina, United States, 27514 | |
Duke University Medical Center | |
Durham, North Carolina, United States, 27710 | |
United States, Pennsylvania | |
University of Pennsylvania | |
Philadelphia, Pennsylvania, United States, 19104 | |
University of Pittsburgh Presbyterian and Shadyside Hospital | |
Pittsburgh, Pennsylvania, United States, 15213 | |
United States, Texas | |
University of Texas SW Medical Center | |
Dallas, Texas, United States, 75390 | |
United States, Washington | |
Puget Sound Blood Center Div of Research | |
Seattle, Washington, United States, 98104 | |
United States, Wisconsin | |
Blood Center of SE Wisconsin | |
Milwaukee, Wisconsin, United States, 53201 |
Principal Investigator: | Susan Assmann, PhD | New England Research Institutes, Inc. |
Principal Investigator: | Mark Brecher, MD | University of North Carolina Hospital |
Principal Investigator: | George Buchanan, MD | University of Texas SW Medical Center |
Principal Investigator: | James Bussel, MD | Weill Medical College of Cornell University |
Principal Investigator: | John Hess, MD, MPH | University of Maryland Medical Center |
Principal Investigator: | Christopher D. Hillyer, MD | Emory University |
Principal Investigator: | Barbara Konkle, MD | University of Pennsylvania |
Principal Investigator: | David Kuter, MD | Massachusetts General Hospital |
Principal Investigator: | Jeffrey McCullough, MD | University of Minnesota |
Principal Investigator: | Janice McFarland, MD | Blood Center of SE Wisconsin |
Principal Investigator: | Paul Ness, MD | Johns Hopkins University |
Principal Investigator: | Thomas Ortel, MD, PhD | Duke University |
Principal Investigator: | Sherrill J. Slichter, MD | Puget Sound Blood Center Div of Research |
Principal Investigator: | Ronald Strauss, MD | University of Iowa |
Principal Investigator: | Darrell Triulzi, MD | University of Pittsburgh Presbyterian and Shadyside Hospital |
Principal Investigator: | James R. Stubbs, MD | Mayo Clinic |
Study ID Numbers: | 326, U01 HL72028, U01 HL72072, U01 HL72191, U01 HL72196, U01 HL72248, U01 HL72289, U01 HL72290, U01 HL72291, U01 HL72299, U01 HL72305, U01 HL72331, U01 HL72346, U01 HL72355, U01 HL72359, U01 HL072283 |
Study First Received: | October 3, 2005 |
Last Updated: | December 20, 2006 |
ClinicalTrials.gov Identifier: | NCT00233246 History of Changes |
Health Authority: | United States: Federal Government |
Hemorrhagic Disorders Hematologic Diseases Blood Coagulation Disorders Vascular Diseases |
Hemorrhage Hemostatic Disorders Hemostatics |
Hemorrhagic Disorders Hematologic Diseases Blood Coagulation Disorders |
Vascular Diseases Cardiovascular Diseases Hemostatic Disorders |